Multinational pharmaceutical firms, particularly those from the U.S., are increasingly recognizing China’s burgeoning innovative drug sector as a strategic gold mine to bolster their global competitiveness. Last month, Lilly’s newly opened Lilly Gateway Labs in Beijing welcomed its first tenant, a Chinese biotechnology company focusing on innovative medicines for neurodegenerative and neurological disorders. This marked the launch of Lilly’s first shared lab platform outside the United States, said David A. Ricks, Chairman and CEO of Eli Lilly and Co. “China’s biopharmaceutical innovation is accelerating at an unprecedented pace,” he noted. China’s vast healthcare market has long been a magnet for global pharmaceutical giants. Notably, the country’s robust biotechnology creativity is now also emerging as a more compelling draw for foreign capital.
Recently, medical tech firm Medtronic opted to tap into China’s biotech advancements, launching a digital healthcare innovation base at the BioPark in the Beijing Economic Technological Development Area (BDA), its first in China. The new facility plans to leverage Beijing’s leading medical resources and innovation momentum to develop disease management solutions based on AI and big data. To date, nearly 5,000 medical and healthcare companies have gathered in the BDA. In addition, Pfizer is set to open its first Beijing-based research center to align clinical trials with global timelines and focus on new product development in oncology. British pharma firm AstraZeneca has also joined the bandwagon by signing a landmark USD2.5 billion agreement to invest in Beijing over the next five years, with the aim of establishing a global strategic R&D center in China’s capital.
“China’s biotechnology sector thrives on a dual engine – Beijing’s constellation of famous medical universities training great minds in biotechnology, coupled with an environment that’s cultivating new company formation,” Ricks from Lilly told Xinhua News Agency. Lilly’s lab platform is designed to accommodate five to eight biotech companies. Ricks confirmed plans to establish additional facilities in Shanghai and other innovation hubs in the country.
“We have hit the optimal moment to develop innovative drugs,” said Guan Xiaoming, Co-founder of 4B Technologies, a Chinese biotech firm that has joined Lilly’s Beijing incubator. Huzur Devletsah, President and General Manager of Lilly China, said: “China’s biopharmaceutical market is rapidly evolving, with significant growth and a strong focus on innovation.” China’s growing appeal for international pharmaceutical giants stems partly from the remarkable global market performance of its homegrown innovative drugs. Akeso, a startup based in Zhongshan, Guangdong province, saw its lung cancer drug outperform Keytruda of MSD, which is known as Merck in the United States, in a head-to-head trial. A Wall Street Journal columnist described it as the DeepSeek moment for China’s biotech industry, albeit in a more “incremental” fashion. On April 1, Hengrui, located in Lianyungang, Jiangsu province, inked an exclusive licensing agreement with MSD for a clinical-stage oral coronary heart disease drug. Hengrui will receive a USD200 million upfront payment from MSD and is eligible for up to USD1.77 billion in royalties on net sales if the product is approved, the China Daily reports.
